Case Study

Helping A Sponsor Overcome A Partial Clinical Hold And Seamlessly Steer Multiple Products Through Development

Source: Veristat, Inc.
GettyImages-836663414 medical team meeting

Amid its clinical development phase, a biotechnology firm specializing in compact-sized operations enlisted the services of Veristat. They aimed to receive assistance with a groundbreaking cell therapy and immunotherapy product platform designed to combat various forms of cancer. Unfortunately, due to a series of chemistry, manufacturing, and control (CMC) inadequacies, one of the products was subjected to a partial clinical hold, triggering numerous information requests from the FDA for all the products within the platform.

In response to this challenge, Veristat's regulatory experts offered customized CMC support, facilitating the sponsor's progress. Uncover how Veristat was able to support the sponsor by accessing the case study below.

access the Case Study!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Supply Leader? Subscribe today.

Subscribe to Clinical Supply Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Supply Leader